MVT-100 Screening Questionnaire
The main purpose of this study is to test a new drug and determine its safety and ability to improve ultrasound images of your heart. An ultrasound image of your heart is called an echocardiogram. A drug designed to improve or enhance the quality of medical images is called a contrast agent. This study will be comparing both good and bad effects of using the study contrast agent, called MVT-100. The study will also be comparing the performance of MVT-100 to the ultrasound contrast agent, Definity®, the current standard of care.
Medications, drugs, and devices must be approved for use by the United States Food and Drug Administration (FDA). The study drug is an investigational treatment, which has not been approved for use in contrast enhanced ultrasound by the FDA in the United States. Safety and efficacy of the study drug as an intravenous infusion and intravenous bolus will be evaluated in this study. The study aims to explore whether the study drug is safe and improves ultrasound images of your heart. The use of the study drug in this study is experimental. Participants in this study will receive different doses of the study drug or Definity® and undergo echocardiograms. The study is randomized, meaning that you will be assigned by chance to a study group. There are two groups in the study, a group receiving the study drug and a group receiving Definity®. Participants will undergo echocardiograms before and after administration of either MVT-100 or Definity® so a suitable baseline is available for comparison.
Saint Luke’s Mid America Heart Institute is recruiting healthy participants for this study. Participants will be financially compensated. If you are interested in being considered for participation, please answer the following questions to begin the process of determining eligibility.